DOI: https://doi.org/10.14710/dmj.v13i3.45004

Correlation between Degree of Leprosy Disability and Serum IL-6 Levels in Patients with Leprosy Reactions: An Observational Study at the Donorojo Jepara Leprosy Hospital Center

*Syifa Nurisma Putri  -  Department of Biomedicine, Faculty of Medicine, Diponegoro University, Jl. Prof. Sudarto, SH, Tembalang, Semarang, Indonesia 50275, Indonesia
Farmaditya Eka Putra Mundhofir orcid scopus  -  Department of Histology, Diponegoro University, Jl. Prof. Sudarto, SH, Tembalang, Semarang, Indonesia 50275, Indonesia
Renni Yuniati orcid scopus  -  Department of Dermatology and Venereology, Diponegoro University, Jl. Prof. Sudarto, SH, Tembalang, Semarang, Indonesia 50275, Indonesia
Noor Wijayahadi scopus  -  Department of Pharmacology, Diponegoro University, Jl. Prof. Sudarto, SH, Tembalang, Semarang, Indonesia 50275, Indonesia
Yora Nindita orcid scopus  -  Department of Pharmacology, Diponegoro University, Jl. Prof. Sudarto, SH, Tembalang, Semarang, Indonesia 50275, Indonesia

Citation Format:
Abstract

Background: Leprosy is an infectious disease caused by Mycobacterium leprae bacteria which is still the focus of a global problem and causes disability in patients. The degree of disability in leprosy is assessed as mild and severe as a result of the inflammatory process. This study aims to determine the relationship between the degree of disability in leprosy and IL-6 serum levels as an inflammatory biomarker in leprosy patients. Methods: A Cross-sectional observational analytical study on leprosy patients aged 20-60 years, not pregnant, and undergoing treatment at Donorojo Jepara Hospital from March to April 2024. Serum IL-6 levels were analyzed using the ELISA method and tested for correlation with the degree of disability leprosy. Results: Statistical analysis of Spearman's correlation rank test shows a p value = 0.279 and the results of the line pattern on the Scatter dot graph are not linear. Conclusion: There is no correlation between serum IL-6 levels and the degree of disability in leprosy patients at Donorojo Jepara Hospital.

Keywords: Degree of Disability in Leprosy, Leprosy, Serum IL-6

Fulltext View|Download
Keywords: Degree of Disability in Leprosy; Leprosy; Serum IL-6

Article Metrics:

Article Info
Section: Original Articles
Language : EN
Recent articles
Correlation between Degree of Leprosy Disability and Serum IL-6 Levels in Patients with Leprosy Reactions: An Observational Study at the Donorojo Jepara Leprosy Hospital Center The effect combination of black seed (nigella sativa) and glibenclamide on blood glucose levels The Relationship of Risk Factors on Quality of Life of Laryngeal Carcinoma Patients after Chemoradiation at Kariadi General Hospital More recent articles
  1. WHO. Global leprosy update, 2018 moving towards a leprosy-free world. World Health Organization [Internet]. 2019 [cited 2023 Jul 27];94:389–412. Available from: http://www.who.int/wer
  2. WHO. Towards zero leprosy: global leprosy (‎Hansen's disease)‎ strategy 2021–2030 [Internet]. WHO, editor. 2021 [cited 2023 Sep 13]. Available from: https://apps.who.int/iris/handle/10665/340774
  3. Putri AI, de Sabbata K, Agusni RI, Alinda MD, Darlong J, de Barros B, et al. Understanding leprosy reactions and the impact on the lives of people affected: An exploration in two leprosy endemic countries. PLoS Negl Trop Dis. 2022 Jun 1;16(6)
  4. Association of Indonesian Dermatology and Venereology Specialists. Clinical Practice Guide for Dermatology and Venereology Specialists in Indonesia. Perdoski. 2017;80–100
  5. Pratama N, Luh Made Mas Rusyati, Prima Sanjiwani Saraswati Sudarsa, IGAA Dwi Karmila, NLP Ratih Vibriyanti Karna. Borderline Lepromatous Leprosy with Severe Erythema Nodosum Leprosum: A Case Report. Periodicals of Skin and Venereology Health Sciences. 2022 Nov 30;34(3):210–6
  6. WHO. Leprosy/Hansen Disease: Management of reactions and prevention of disabilities technical guidance. 2020; Available from: http://apps.who.int/bookorders
  7. Walker SL. Leprosy reactions. In: Scollard DM, Gillis TP, editors. The International Textbook of Leprosy [Internet]. London: London School of Hygiene and Tropical Medicine; 2020 [cited 2023 Jul 25]. p. 1–30. Available from: https://internationaltextbookofleprosy.org/authors/walker
  8. Pinheiro RO, Schmitz V, Silva BJA, Dias AA, de Souza BJ, de Mattos Barbosa MG et al. Innate immune response in leprosy. Front Immunol. 2018 Mar 28;9:518
  9. Luo Y, Kiriya M, Tanigawa K, Kawashima A, Nakamura Y, Ishii N, et al. Host-Related Laboratory Parameters for Leprosy Reactions. Front Med (Lausanne) [Internet]. 2021;8. Available from: https://www.frontiersin.org/articles/10.3389/fmed.2021.694376
  10. Saini C, Siddiqui A, Ramesh V, Nath I. Leprosy Reactions Show Increased Th17 Cell Activity and Reduced FOXP3+ Tregs with Concomitant Decrease in TGF-β and Increase in IL-6. PLoS Negl Trop Dis. 2016 Apr 1;10(4):1–21
  11. Yuniati R, Agusni I. IL-6 Levels in Leprosy Patients with Reversal Reactions. Pakistan Journal of Health & Medical Sciences [Internet]. 2018 [cited 2023 Sep 13];12(3):1340-2. Available from: https://pjmhsonline.com/2018/july_sep/pdf/1340.pdf
  12. Yang J, Li X, Sun Y, Zhang L, Jin G, Li G, et al. Global epidemiology of leprosy from 2010 to 2020: A systematic review and meta-analysis of the proportion of sex, type, grade 2 deformity and age. Vol. 116, Pathogens and Global Health. Taylor and Francis Ltd.; 2022. p. 467–76
  13. N. S NA, Muniroh M, Kusumaningrum N, PM FE, Yuniati R. Clitoria ternatea L. Extract as Adjuvant Therapy on Reducing IL-6 Levels in Reversal Reaction. Biosaintifika: Journal of Biology & Biology Education. 2023 Apr 30;15(1)
  14. Sarode G, Sarode S, Anand R, Patil S, Jafer M, Baeshen H, et al. Epidemiological aspects of leprosy. Vol. 66, Disease-a-Month. Mosby Inc.; 2020
  15. Nazli PAN, Lubis SR, Khairina. Correlation between the stress scale and cortisol levels in leprosy patients. Bali Medical Journal. 2021;10(1):500-4
  16. Pinsornsak P, Niempoog S. The efficacy of Curcuma Longa L. extract as an adjuvant therapy in primary knee osteoarthritis: a randomized control trial. J Med Assoc Thai. 2012 Jan;95(Suppl-1):S51-8
  17. Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology. Philadelphia: Elsevier Inc. 2018;9th ed
  18. Peng Y, Ao M, Dong B, Jiang Y, Yu L, Chen Z, et al. Anti-inflammatory effects of curcumin in inflammatory diseases: Status, limitations and countermeasures. Vol. 15, Drug Design, Development and Therapy. Dove Medical Press Ltd; 2021. p. 4503–25
  19. Saini C, Srivastava RK, Tarique M, Kurra S, Khanna N, Ramesh V, et al. Elevated IL-6R on CD4+ T cells promotes IL-6 driven Th17 cell responses in patients with T1R leprosy reactions. Sci Rep. 2020 Dec 1;10(1)
  20. Angst DBM, Pinheiro RO, Vieira JS da S, Cobas RA, Hacker M de AVB, Pitta IJR, et al. Cytokine Levels in Neural Pain in Leprosy. Front Immunol. 2020 Jan 24;11
  21. Bäckryd E. Pain in the blood? Envisioning mechanism-based diagnoses and biomarkers in clinical pain medicine. Diagnostics. 2015;5(1):84–95
  22. Andrade P, Hoogland G, Garcia MA, Steinbusch HW, Daemen MA, Visser-Vandewalle V. Elevated IL-1b and IL-6 levels in lumbar herniated discs in patients with sciatic pain. European Spine Journal. 2013 Apr;22(4):714–20
  23. Ren T, Cidlowski JA. Antiinflammatory Action of Glucocorticoids-New Mechanisms for Old Drugs. New England Journal of Medicine [Internet]. 2005;353:1711-23. Available from: www.nejm.org

Last update:

No citation recorded.

Last update:

No citation recorded.